EP Patent

EP2341903A1 — Cannabinoids for use in treating or preventing cognitive impairment and dementia

Assigned to Bionorica Research GmbH · Expires 2011-07-13 · 15y expired

What this patent protects

The present invention is directed to the use of at least one cannabinoid in the manufacture of a medicament for use in treating or preventing or in the manufacture of a dietary supplement for preventing a disease or condition benefiting from a reduced activity of the enzyme indol…

USPTO Abstract

The present invention is directed to the use of at least one cannabinoid in the manufacture of a medicament for use in treating or preventing or in the manufacture of a dietary supplement for preventing a disease or condition benefiting from a reduced activity of the enzyme indoleamine 2,3-dioxygenase (IDO). The disease or condition to be treated or prevented is preferably selected from cognitive impairment or any kind of dementia.

Drugs covered by this patent

Patent Metadata

Patent number
EP2341903A1
Jurisdiction
EP
Classification
—
Expires
2011-07-13
Drug substance claim
No
Drug product claim
No
Assignee
Bionorica Research GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.